Page last updated: 2024-09-05

erlotinib hydrochloride and Testicular Neoplasms

erlotinib hydrochloride has been researched along with Testicular Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amatruda, JF; Ateek, C; Budhipramono, A; Chen, KS; Frazier, AL; Fustino, NJ; Kapur, P; Laetsch, TW; Looijenga, LHJ; Lum, L; Rakheja, D; Shukla, AA; Stroup, EK; Stuart, SH; Yamaguchi, K1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Testicular Neoplasms

ArticleYear
EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin Receptor Common gamma Subunit; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Sirolimus; Testicular Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays

2018